These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 24186142)
1. Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions. Ang DC; Warrick AL; Shilling A; Beadling C; Corless CL; Troxell ML Mod Pathol; 2014 May; 27(5):740-50. PubMed ID: 24186142 [TBL] [Abstract][Full Text] [Related]
2. Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions. Troxell ML; Brunner AL; Neff T; Warrick A; Beadling C; Montgomery K; Zhu S; Corless CL; West RB Mod Pathol; 2012 Jul; 25(7):930-7. PubMed ID: 22460814 [TBL] [Abstract][Full Text] [Related]
3. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations. Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004 [TBL] [Abstract][Full Text] [Related]
4. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Troxell ML; Levine J; Beadling C; Warrick A; Dunlap J; Presnell A; Patterson J; Shukla A; Olson NR; Heinrich MC; Corless CL Mod Pathol; 2010 Jan; 23(1):27-37. PubMed ID: 19898424 [TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217 [TBL] [Abstract][Full Text] [Related]
6. Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype. Jacob T; Gray JW; Troxell M; Vu TQ Breast Cancer Res Treat; 2016 Oct; 159(3):575-83. PubMed ID: 27581127 [TBL] [Abstract][Full Text] [Related]
7. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma. Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210 [TBL] [Abstract][Full Text] [Related]
8. Lobular neoplasia: frequency and association with other breast lesions. Gomes DS; Balabram D; Porto SS; Gobbi H Diagn Pathol; 2011 Aug; 6():74. PubMed ID: 21827679 [TBL] [Abstract][Full Text] [Related]
9. Phylogenetic analysis of combined lobular and ductal carcinoma of the breast. Kobayashi H; Nakai T; Nakanishi Y; Esumi M; Masuda S Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396426 [TBL] [Abstract][Full Text] [Related]
10. Whole-exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. D'Alfonso TM; Pareja F; Da Cruz Paula A; Vahdatinia M; Gazzo A; Ferrando L; da Silva EM; Cheng E; Sclafani L; Chandarlapaty S; Zhang H; Hoda SA; Wen HY; Brogi E; Weigelt B; Reis-Filho JS J Pathol Clin Res; 2021 Mar; 7(2):113-120. PubMed ID: 33263939 [TBL] [Abstract][Full Text] [Related]
11. Juvenile papillomatosis of the breast (Swiss cheese disease) has frequent associations with PIK3CA and/or AKT1 mutations. Guillet C; Rechsteiner M; Bellini E; Choschzick M; Moskovszky L; Dedes K; Papassotiropoulos B; Varga Z Hum Pathol; 2020 Apr; 98():64-73. PubMed ID: 32088208 [TBL] [Abstract][Full Text] [Related]
12. Inter-observer variability between general pathologists and a specialist in breast pathology in the diagnosis of lobular neoplasia, columnar cell lesions, atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Gomes DS; Porto SS; Balabram D; Gobbi H Diagn Pathol; 2014 Jun; 9():121. PubMed ID: 24948027 [TBL] [Abstract][Full Text] [Related]
13. Molecular alterations in columnar cell lesions of the breast. Dabbs DJ; Carter G; Fudge M; Peng Y; Swalsky P; Finkelstein S Mod Pathol; 2006 Mar; 19(3):344-9. PubMed ID: 16400324 [TBL] [Abstract][Full Text] [Related]
14. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Abdel-Fatah TM; Powe DG; Hodi Z; Lee AH; Reis-Filho JS; Ellis IO Am J Surg Pathol; 2007 Mar; 31(3):417-26. PubMed ID: 17325484 [TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression. Shah V; Nowinski S; Levi D; Shinomiya I; Kebaier Ep Chaabouni N; Gillett C; Grigoriadis A; Graham TA; Roylance R; Simpson MA; Pinder SE; Sawyer EJ Breast Cancer Res; 2017 Jan; 19(1):7. PubMed ID: 28095868 [TBL] [Abstract][Full Text] [Related]
16. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755 [TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761 [TBL] [Abstract][Full Text] [Related]
19. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma. Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376 [TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations in in situ and invasive breast carcinomas. Miron A; Varadi M; Carrasco D; Li H; Luongo L; Kim HJ; Park SY; Cho EY; Lewis G; Kehoe S; Iglehart JD; Dillon D; Allred DC; Macconaill L; Gelman R; Polyak K Cancer Res; 2010 Jul; 70(14):5674-8. PubMed ID: 20551053 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]